SG11201808266QA - Hepatitis b treatment vaccine on the basis of inactivated, fully recombinant hansenula cells expressing hbsag - Google Patents

Hepatitis b treatment vaccine on the basis of inactivated, fully recombinant hansenula cells expressing hbsag

Info

Publication number
SG11201808266QA
SG11201808266QA SG11201808266QA SG11201808266QA SG11201808266QA SG 11201808266Q A SG11201808266Q A SG 11201808266QA SG 11201808266Q A SG11201808266Q A SG 11201808266QA SG 11201808266Q A SG11201808266Q A SG 11201808266QA SG 11201808266Q A SG11201808266Q A SG 11201808266QA
Authority
SG
Singapore
Prior art keywords
inactivated
hepatitis
basis
cells expressing
treatment vaccine
Prior art date
Application number
SG11201808266QA
Other languages
English (en)
Inventor
Hemu Wang
Changhua Wang
Jun Yang
Original Assignee
Hemu Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemu Wang filed Critical Hemu Wang
Publication of SG11201808266QA publication Critical patent/SG11201808266QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/78—Hansenula

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11201808266QA 2016-03-25 2017-03-16 Hepatitis b treatment vaccine on the basis of inactivated, fully recombinant hansenula cells expressing hbsag SG11201808266QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610180329.XA CN105727280B (zh) 2016-03-25 2016-03-25 基于表达HBsAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
PCT/CN2017/076933 WO2017162091A1 (zh) 2016-03-25 2017-03-16 基于表达HBsAg的失活全重组汉逊酵母细胞的乙肝治疗疫苗

Publications (1)

Publication Number Publication Date
SG11201808266QA true SG11201808266QA (en) 2018-11-29

Family

ID=56252047

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808266QA SG11201808266QA (en) 2016-03-25 2017-03-16 Hepatitis b treatment vaccine on the basis of inactivated, fully recombinant hansenula cells expressing hbsag

Country Status (7)

Country Link
US (1) US10653772B2 (zh)
EP (1) EP3434281A4 (zh)
JP (1) JP6821780B2 (zh)
CN (1) CN105727280B (zh)
EA (1) EA201892179A1 (zh)
SG (1) SG11201808266QA (zh)
WO (1) WO2017162091A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105727279B (zh) * 2016-03-25 2019-01-15 汪和睦 基于表达HBsAg和HBcAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
CN105797151A (zh) * 2016-03-25 2016-07-27 汪和睦 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗
CN112048445A (zh) * 2020-09-15 2020-12-08 天津和睦健民生物科技有限公司 汉逊酵母重组covid-19病毒样包膜颗粒疫苗细胞株
CN114177285A (zh) * 2022-01-14 2022-03-15 上海恒赛生物科技有限公司 一种免疫佐剂及其在乙肝治疗性疫苗中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1322288A4 (en) * 2000-09-08 2005-02-23 Epimmune Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO HEPATITIS B VIRUS WITH PEPTIDE AND NUCLEIC ACID COMPOSITIONS
CN100347287C (zh) * 2004-09-30 2007-11-07 汪和睦 一种重组多形汉逊酵母菌及其构建方法与应用
CN101314761B (zh) * 2007-05-31 2012-05-30 上海生物制品研究所有限责任公司 高拷贝表达重组乙肝表面抗原的毕赤酵母及其制法和应用
CN102038948B (zh) * 2009-10-10 2013-04-10 复旦大学 一种控制乙型肝炎病毒持续性感染的疫苗
CN102198270B (zh) * 2011-05-16 2012-06-27 大连汉信生物制药有限公司 一种含铝佐剂乙肝疫苗的制备方法
CN104232661A (zh) * 2013-06-08 2014-12-24 北京天坛生物制品股份有限公司 重组dna序列、酵母菌、乙肝表面抗原制备方法及疫苗
CN105797151A (zh) * 2016-03-25 2016-07-27 汪和睦 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗

Also Published As

Publication number Publication date
EP3434281A1 (en) 2019-01-30
CN105727280B (zh) 2021-01-19
WO2017162091A1 (zh) 2017-09-28
EA201892179A1 (ru) 2019-03-29
EP3434281A4 (en) 2019-11-13
JP6821780B2 (ja) 2021-01-27
US20190216921A1 (en) 2019-07-18
CN105727280A (zh) 2016-07-06
JP2019509347A (ja) 2019-04-04
US10653772B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
HK1255847A1 (zh) 針對乙型肝炎病毒的疫苗
MA50813A (fr) Vaccins contre le virus d'epstein-barr
IL280459A (en) Phosphoramidates for the treatment of hepatitis B virus
HK1223931A1 (zh) 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
IL275427A (en) Hepatitis virus vaccines HBV) B) and their uses
SG11202003700TA (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
IL265921A (en) Transgenic meganonucleases specific for recognition sequences in the hepatitis b virus genome
SG10201913958QA (en) Modulation of hepatitis b virus replication
SG11201808266QA (en) Hepatitis b treatment vaccine on the basis of inactivated, fully recombinant hansenula cells expressing hbsag
SI3137078T1 (sl) Zdravljenje okužbe s hepatitis delta virusom
EP3515929A4 (en) THERAPEUTIC VACCINE AGAINST HEPATITIS B
SG11201808268UA (en) Recombinant hansenula-based high dosage hepatitis b vaccine
PT3491139T (pt) Vetores lentivirais para expressão de antigénios de vírus da hepatite b (hbv)
EP3434282A4 (en) THERAPEUTIC VACCINE AGAINST HEPATITIS B BASED ON AN INACTIVATED WHOLE RECOMBINANT HANSENULA CELL EXPRESSING HBSAG AND HBCAG
EP3211073A4 (en) Replicative vaccinia virus vector hiv vaccine
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201702193D0 (en) Hepatitis E virus vaccine
PL3244921T3 (pl) Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV
HK1221859A2 (zh) 種乙型肝炎疫苗及其製備工藝